You are here

  • Home
  • Archive
  • Volume 77, Issue 11
  • Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate

Article metrics

Article menu

Download PDFPDF

Clinical and epidemiological research
Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate

 

Online download statistics by month:

Online download statistics by month: August 2018 to March 2024

AbstractFullPdf
Aug 201811961238407
Sep 201856961493
Oct 2018684683198
Nov 2018383382131
Dec 201820520563
Jan 201910810525
Feb 2019747328
Mar 2019939127
Apr 2019727228
May 2019696722
Jun 2019484817
Jul 2019706823
Aug 2019696824
Sep 2019616228
Oct 2019585628
Nov 2019474715
Dec 2019534920
Jan 2020494219
Feb 2020262611
Mar 2020303017
Apr 2020272624
May 2020393830
Jun 202021217
Jul 2020252521
Aug 2020242512
Sep 2020393226
Oct 2020454321
Nov 2020535022
Dec 2020494617
Jan 2021222110
Feb 202111119
Mar 2021343220
Apr 2021201812
May 2021262414
Jun 2021373615
Jul 2021272219
Aug 2021262220
Sep 2021303014
Oct 2021262622
Nov 2021323215
Dec 2021343317
Jan 2022202012
Feb 202226244
Mar 2022323119
Apr 2022463810
May 202245378
Jun 2022474813
Jul 2022372815
Aug 2022404011
Sep 2022534719
Oct 202229284
Nov 2022353210
Dec 2022282612
Jan 2023414331
Feb 202341399
Mar 20239103
Apr 2023131211
May 2023252119
Jun 2023373714
Jul 202329269
Aug 2023272413
Sep 2023292817
Oct 2023413912
Nov 202341402
Dec 2023302811
Jan 2024422718
Feb 2024282412
Mar 2024302311
Total551254591920